Module 04G · Lesson 02

Submission Section Drafting and Verification — The Highest-Stakes Workflow

Reading time: 20 minutes Track: Role Path — Regulatory Affairs Prerequisites: Module 04G · Lesson 01

What this lesson does

This is the lesson where the most regulatory value can be created and the most regulatory risk can be incurred. Submission section drafting — IND modules, NDA/BLA sections, supplements, briefing documents — is documentation-heavy work where AI can dramatically accelerate output. It's also where errors get printed in the regulatory record.

By the end of this lesson, you'll be able to:

1. Use AI to draft submission sections that meet quality standards with appropriate verification
2. Apply the specific verification protocols that protect against AI failure modes in regulatory content
3. Document AI use in a way that survives inspection
4. Recognize when AI should not be used regardless of organizational policy

01 · The submission documentation landscape

Submission documents include:

• IND modules (Module 1 administrative, Module 2 summary, Module 3 CMC, Module 4 nonclinical, Module 5 clinical)
• NDA/BLA modules (similar structure, broader scope)
• Supplements (efficacy, safety, manufacturing, label)
• Annual reports
• DSURs (Development Safety Update Reports)
• PSURs / PBRERs (post-approval safety)
• Briefing documents for various meeting types
• Response documents (to deficiency letters, IRs, requests for information)

Each has standardized structure, required content, and conventions. The structure makes AI drafting tractable. The conventions make verification critical.

02 · Where AI is most useful by document type

Highest leverage — narrative summary sections

Module 2 of CTD submissions is the clinical/nonclinical summary. It synthesizes detailed source documents into shorter narratives.

AI helps significantly because:

• Source material is provided (you have the underlying CSRs, study reports)
• Synthesis is what AI does well
• Conventions are well-documented
• Structure is prescribed

High leverage — methods and design sections

Methods descriptions, study design summaries, manufacturing process descriptions.

AI helps because:

• Source material exists (protocols, master batch records)
• Translation to submission language is structured
• Standards are well-published

Moderate leverage — discussion and interpretation sections

Sections that require interpretive judgment (discussions of efficacy findings, integrated safety summaries, benefit-risk assessments).

AI helps less because:

• Interpretation is the value
• AI defaults to generic framing
• The work being done is judgment, not just translation

Low leverage — administrative and procedural content

Cover letters, applicant information, modular references.

AI helps modestly. Templates work as well; AI doesn't add much.

Use carefully — clinical narrative sections

Subject narratives (typically for SAEs in safety summaries).

These contain subject-level information; require Tier 4 environment; require thorough verification against source.

03 · The section drafting workflow

A pattern that works across submission section types.

Step 1 — Define the section

Senior regulatory writer drafting Section [X.X] of [document type] for [program].

Section requirements (per [ICH-E3 / FDA guidance / template]):
- Purpose: [what this section accomplishes]
- Required content: [list]
- Standard length: [target]
- Cross-references: [to which other sections]
- Conventions: [voice, tense, format]

Source documents available: [list]

Initial outline of what this section needs to convey: [your bullets]

Don't draft yet — confirm you understand the requirements and ask any clarifying questions.

This setup step seems heavy. It saves significant time in drafting and revision.

Step 2 — Draft with explicit constraints

Now draft Section [X.X] using:
- The structure above
- Information ONLY from the source documents I've attached
- Conventions: [past tense, formal, no marketing language, etc.]
- Cross-references in format [our convention]
- Length target: [N words]

For any information needed that isn't in my source documents, mark as [INFORMATION NEEDED] rather than inventing.

For any quantitative value, cite the source: [Table X.X.X] or [Section X.X.X].

[Source documents]

The "only from source documents" instruction is critical. Without it, AI may import information from training that's not in your data.

Step 3 — Verification (the load-bearing step)

For submission content, verification is non-negotiable. The protocol:

Factual verification:

• Every number traced to a source document
• Every cross-reference verified to exist
• Every citation matches the actual reference

Completeness verification:

• All required elements per guidance present
• Standard sub-headings present
• Required tables and figures included

Consistency verification:

• Numbers match across sections
• Terminology consistent with prior sections and prior submissions
• Cross-references resolve

Regulatory verification:

• Aligns with current applicable guidance
• Consistent with prior agency interactions
• Doesn't make claims beyond what data supports

This verification can take longer than the drafting did. That's appropriate; verification is the value-add at this stage.

Step 4 — Senior review

Per your organization's SOP. AI-touched content typically requires explicit senior regulatory review.

Step 5 — Documentation

Formal documentation of AI use:

• Tool, model, version
• Date(s) of drafting
• Section(s) involved
• What source material was provided
• Verification steps performed and by whom
• Senior review status

This documentation is part of the submission record.

04 · The seven specific failure modes for submission AI

Failure 1 — Information not in source documents

AI imports facts from training that aren't in the source material you provided. Looks plausible. Isn't traceable.

Defense: Explicit "only from source" instruction. Verification that every fact traces to source.

Failure 2 — Incorrect cross-references

AI generates cross-references that look correct but don't actually point to the right section.

Defense: Verify every cross-reference resolves correctly. Use automated tools where possible.

Failure 3 — Outdated guidance references

AI references a guidance version that's been superseded.

Defense: Verify guidance currency before relying on AI's references.

Failure 4 — Inconsistent terminology

AI uses different terms for the same concept across sections (or differs from the conventions in your prior submissions).

Defense: Provide a terminology document; verify consistency across sections.

Failure 5 — Claims that exceed data

AI uses words like "demonstrated," "established," "proven" where data supports weaker claims like "consistent with," "suggestive of," "preliminary evidence for."

Defense: Explicitly constrain in the prompt; verify language in review.

Failure 6 — Promotional language

AI defaults to slightly more positive framing than regulatory norms allow. Adjectives, intensifiers, framing devices that creep toward marketing.

Defense: Strip in review. Build a "forbidden words" list for your team.

Failure 7 — Subtle attribution errors

AI attributes a finding to the wrong study, the wrong subgroup, or the wrong analysis.

Defense: Verify every attribution against the source.

05 · The "show your work" discipline

A specific discipline that protects against errors and creates an audit trail:

For each AI-drafted submission section, maintain a working document that shows:

• The prompt used
• The source documents provided
• The first draft from AI
• The verification notes (what was checked, what was changed)
• The final version
• The senior review

This working document is internal — it's not part of the submission. But it lives in the project file. If anyone asks (auditor, future colleague, you in six months), the answer to "how was this section produced" is documented.

This discipline takes 15-20% additional time. It's the kind of investment that pays for itself the first time it's needed.

06 · Specific section types — guidance

Module 2.5 — Clinical Overview

Synthesizes the clinical development program for the indication.

AI's role: Initial drafting from CSRs and integrated analyses. Strong fit for section structure and standard content.

Verification focus: Every claim traced to source. Cross-references to detailed Module 2.7 sections. Consistency with proposed labeling claims.

Module 2.7 — Clinical Summary

The detailed clinical summary. Multiple sub-sections (efficacy, safety, special populations).

AI's role: Initial drafting of standard sub-sections from CSRs and ISS/ISE.

Verification focus: Statistical claims (need biostat review), safety signal language, subgroup analyses, cross-references.

Module 5.3 — Clinical Study Reports

Detailed CSRs for individual studies.

AI's role: Drafting standard sections (methods, demographics, disposition) from study source documents.

Verification focus: Tables and figures, exact subject counts, deviation tracking, narrative consistency.

Briefing documents for FDA meetings

Pre-meeting documents that frame discussions.

AI's role: Structure, question articulation, supporting data presentation.

Verification focus: Position consistency with prior interactions, question precision, supporting data accuracy.

Response documents

Replies to FDA queries, deficiency letters, requests for information.

AI's role: Structuring responses to ensure all questions addressed.

Verification focus: Every question explicitly answered, evidence supporting answers, consistency with submission.

07 · A worked example

A realistic scenario.

Setting: You're drafting Section 2.7.4 (Summary of Clinical Safety) for an NDA. The section is ~60-100 pages and pulls from the integrated safety summary (ISS), individual CSRs, and aggregate analyses.

Step 1 — Confirm policy and environment

Confirm your organization's policy on AI in NDA submission content. Assuming permitted with controls: proceed in zero-retention enterprise environment.

Step 2 — Decompose

A 60-100 page section is too large for a single AI prompt. Decompose:

• 2.7.4.1 Methods of safety evaluation
• 2.7.4.2 Overall extent of exposure
• 2.7.4.3 Adverse events
• 2.7.4.4 Clinical laboratory evaluations
• 2.7.4.5 Vital signs, physical findings
• 2.7.4.6 Safety in special groups
• 2.7.4.7 Additional safety data
• ...

Each sub-section gets its own drafting workflow.

Step 3 — Sub-section drafting (example: 2.7.4.3 Adverse events)

Senior regulatory writer drafting Section 2.7.4.3 (Adverse Events) of NDA for [program].

Standard structure per ICH-E3 and your template:
1. Brief summary of adverse events
2. Display of adverse events
3. Analysis of adverse events
4. Listing of adverse events by subject

Source material attached: ISS Tables 7.1-7.18, CSRs for Studies XX, YY, ZZ.

Conventions: Past tense, formal, no promotional language. Cross-references to ISS in format [ISS Table X.X].

Draft the section using ONLY the attached source. For each AE count, cite the source table. For any claim, ensure it's supported by the data. Mark anything I haven't provided as [DATA NEEDED].

Length target: 15-20 pages.

AI drafts. You verify every number, every reference, every claim.

Step 4 — Cross-section consistency

After all sub-sections are drafted, prompt for consistency check:

Review the following sub-sections of 2.7.4 for cross-section consistency:
- Subject counts match across sections
- AE categorizations consistent
- Cross-references resolve
- Terminology consistent
- Claims supported by data presented earlier

Flag any inconsistencies.

Step 5 — Senior review

Per SOP.

Step 6 — Documentation

Complete working document for the section, archived with the submission file.

Total time: ~6 weeks for what would have taken 10-12 weeks. Quality at or above standard. Documentation defensible.

08 · When NOT to use AI in submission work

A specific list of situations where AI use is inappropriate regardless of organizational policy:

• Subject narratives for SAEs with sensitive details — too easy to leak information, too hard to verify completely
• Content involving attorney-client privileged matters — privilege risk
• Content where the current FDA position is unclear or recent — AI may not know
• Strategy documents that involve specific competitor data not yet public — confidentiality risk
• Content where your organization's policy doesn't yet permit — policy compliance

These aren't bright lines (Module 03 Lesson 01) but they're situations where the calculation tilts away from AI use.

09 · Knowledge check

Three questions.

Q1. Why is the "only from source documents" instruction specifically called out as critical?

a) It produces shorter outputs b) Without it, AI may import information from training that's not in your data — looks plausible but isn't traceable, creating verification problems and potential submission errors c) It's required by FDA d) Source documents are easier to read

Q2. Why does the verification step often take longer than the drafting step in submission AI use?

a) AI is slow b) Verification is the value-add at the submission stage; for content that goes to regulators, every fact, cross-reference, claim, and citation must be verified — that's where the work is, not the typing c) Verification tools are slow d) Senior review takes a long time

Q3. Why does this lesson recommend maintaining a "working document" alongside the submission section?

a) FDA requires it b) It creates an internal audit trail showing the prompt, source material, draft, verification notes, final version, and senior review — protecting against errors and demonstrating responsible AI use to anyone who asks c) It makes submissions longer d) It's a marketing requirement

Answers: Q1: b · Q2: b · Q3: b

10 · What's next

Lesson 03: Health authority interaction preparation.

End of Lesson 02.